Article

Expression of gremlin, a bone morphogenetic protein antagonist, in human diabetic nephropathy

Department of Medicine, The Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Mater Misericordiae University Hospital, Dublin, Ireland.
American Journal of Kidney Diseases (Impact Factor: 5.76). 07/2005; 45(6):1034-9. DOI: 10.1053/j.ajkd.2005.03.014
Source: PubMed

ABSTRACT We report the induction of gremlin, a bone morphogenetic protein antagonist, in cultured human mesangial cells exposed to high glucose and transforming growth factor beta (TGF-beta) levels in vitro and kidneys from diabetic rats in vivo.
Gremlin expression was assessed in human diabetic nephropathy by means of in situ hybridization, immunohistochemistry, and real-time polymerase chain reaction and correlated with clinical and pathological indices of disease.
Gremlin was not expressed in normal human adult kidneys. Conversely, abundant gremlin expression was observed in human diabetic nephropathy. Although some gremlin expression was observed in occasional glomeruli, gremlin expression was most prominent in areas of tubulointerstitial fibrosis, where it colocalized with TGF-beta expression. Gremlin messenger RNA levels correlated directly with renal dysfunction, determined by means of serum creatinine level, but not with proteinuria level. There was a strong correlation between gremlin expression and tubulointerstitial fibrosis score.
In aggregate, these results indicate that the developmental gene gremlin reemerges in the context of tubulointerstitial fibrosis in diabetic nephropathy and suggests a role for TFG-beta as an inducer of gremlin expression in this context.

0 Bookmarks
 · 
96 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Diabetic Kidney Disease (DKD) occurs in upwards of 30% of patient with type 2 diabetes mellitus (T2DM) and is characterised at source by a maladaptive response in the renal parenchyma to exposure to a glucotoxic/lipotoxic diabetic milieu that courses coincident with hypertension. The consequence of these maladaptive responses is progressive renal injury which is exacerbated by the development of a chronic inflammatory infiltrate associated with the development of tubulointerstitial fibrosis. The evolution of tubulointerstitial fibrosis correlates with the loss of functional renal mass and descent towards renal failure.Transforming growth factor beta-1 (TGF-β1) is a recognised mediator of the pro-fibrotic response of mesangial cells and renal tubular epithelial cells to hyperglycaemia. While euglycaemia remains the goal in the treatment of T2DM, prevention, arrest and reversal of microvascular complications such as DKD may be assisted by pharmacological modulation of the effectors of of glucotoxicity such as TGF-β1.This review focuses on describing how through reductionist in vitro experimentation focusing on TGF-β1 related responses to hyperglycaemia, we have identified Induced by High Glucose-1 (IHG-1), Induced by High Glucose-2 (IHG-2/Grem 1) and the lipoxin inducible microRNA let-7c as potential targets for harnessing new therapeutic approaches to limit the bioactivity of TGF-β1 in DKD.This article is protected by copyright. All rights reserved
    Experimental physiology 07/2014; 99(9). DOI:10.1113/expphysiol.2014.078774 · 2.87 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: To study the effect of lycopene on ameliorating renal function of diabetic nephropathy.
  • [Show abstract] [Hide abstract]
    ABSTRACT: The peritoneal membrane becomes damaged in patients on peritoneal dialysis (PD). Gremlin 1 (GREM1) inhibits bone morphogenic proteins (BMPs) and plays a role in development and fibrosis. We evaluated the role of gremlin in peritoneal fibrosis and angiogenesis. In a cohort of 32 stable PD patients, GREM1 concentration in the peritoneal effluent correlated with measures of peritoneal membrane damage. AdGrem1, an adenovirus to overexpress gremlin in the mouse peritoneum, induced submesothelial thickening, fibrosis, and angiogenesis in C57BL/6 mice, which was associated with decreased expression of BMP4 and BMP7. There was evidence of mesothelial cell transition to a mesenchymal phenotype with increased α smooth muscle actin expression and suppression of E-cadherin. Some of the GREM1 effects may be reversed with recombinant BMP7 or a pan-specific transforming growth factor β (TGF-β) antibody. Neovascularization was not inhibited with a TGF-β antibody, suggesting a TGF-β–independent angiogenic mechanism. Swiss/Jackson Laboratory (SJL) mice, which are resistant to TGF-β–induced peritoneal fibrosis, responded in a similar fashion to AdGrem1 as did C57BL/6 mice with fibrosis, angiogenesis, and mesothelial-to-mesenchymal transition. GREM1 was associated with up-regulated TGF-β expression in both SJL and C57BL/6 mice, but SJL mice demonstrated a defective TGF-β–induced GREM1 expression. In summary, GREM1 induces fibrosis and angiogenesis in mouse peritoneum and is associated with increased solute transport in these PD patients.
    American Journal Of Pathology 11/2014; 184(11). DOI:10.1016/j.ajpath.2014.07.018 · 4.60 Impact Factor